Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02441283 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Phase 2 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 384
- Enrollment target
NCT02441283 is a Phase 2 study that has completed, run by AbbVie. The registered enrollment target is 384 participants.
The verdict
NCT02441283, a Phase 2 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 384 participants
- Enrollment target
Study Summary
This was a long-term follow-up study to evaluate the durability of sustained virologic response (SVR), persistence of direct-acting antiviral agent (DAA) resistance, and clinical outcomes for participants who received glecaprevir (ABT-493) and/or pibrentasvir (ABT-530) in prior AbbVie Phase 2 or 3 clinical studies for the treatment of chronic hepatitis C virus (HCV) infection.
Interventions
- DRUG ABT-493
- DRUG ABT-530
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 384 participants |
| Start Date | 2015-06-22 |
| Est. Completion | 2019-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02441283
The ClinicalTrials.gov registry entry for NCT02441283 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 384 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ABT-493 is the first listed.
NCT02441283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02441283 about?
NCT02441283 is a clinical study titled "A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530". This was a long-term follow-up study to evaluate the durability of sustained virologic response (SVR), persistence of direct-acting antiviral agent (DAA) resistance, and clinical outcomes for participants who received glecaprevir (ABT-493) and/or pibrentasvir (ABT-530) in prior AbbVie Phase 2 or 3 c...
What is the current status of trial NCT02441283?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 384 participants. The study started on 2015-06-22. Estimated completion is 2019-10-15.
What interventions are being tested in trial NCT02441283?
The interventions under investigation include: ABT-493 (DRUG), ABT-530 (DRUG).
Who is sponsoring clinical trial NCT02441283?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.